Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • kgosche@partek.com
    Member
    • Aug 2016
    • 16

    #1

    Analyzing Cell-Free DNA Seq Data from Cancer Patients to find Actionable Variants

    Webinar:
    How to Analyze Cell-Free DNA Sequencing Data from Cancer Patients to Identify Clinically Actionable Variants

    In this webinar, whole exome sequencing data of tumor tissue and cell-free DNA derived from two cancer patients will be used to demonstrate how non-invasive liquid biopsies from the blood have the potential to aid in precision medicine. Using Partek® Flow® software, a powerful and easy-to-use bioinformatics tool, we will analyze raw sequence data from individuals with metastatic sarcoma and metastatic breast cancer to identify clinically actionable variants.

    You will learn how to:
    • Align and filter whole exome sequencing data
    • Detect variants from tumor and cell-free DNA
    • Perform annotation and filtering to prioritize variants

    Live Sessions Offered:
    • September 27, 2017 at 10am SGT (Singapore)
    • September 28, 2017 at 2pm GMT (London)
    • September 28, 2017 at 2pm EDT (Boston)

    REGISTER NOW

Latest Articles

Collapse

  • SEQadmin2
    16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
    by SEQadmin2




    NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
    Today, 06:46 AM
  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-28-2026, 09:57 AM
0 responses
22 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-28-2026, 09:51 AM
0 responses
15 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
68 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
48 views
0 reactions
Last Post SEQadmin2  
Working...